Jessica P. Hwang, M.D., MPH
Department of General Internal Medicine, Division of Internal Medicine
About Dr. Hwang
Jessica P. Hwang, MD, MPH, DipABLM
I am a Professor in the Department of General Internal Medicine at The University of Texas MD Anderson Cancer Center. My clinical and research work has focused on hepatitis B screening to prevent reactivation and serious liver-related adverse events due to systemic anticancer therapy. I have served as principal investigator on NIH and CPRIT grants aimed to prevent liver disease among patients with or at risk for cancer, and I have worked on teams to coauthor national guidelines on hepatitis B from the American Association for the Study of Liver Diseases and American Society of Clinical. After taking a sabbatical in 2023-2024 where I became board certified in Lifestyle Medicine and initiated training in health coaching and mindfulness-based stress reduction, my work shifted towards the management of metabolic syndrome and metabolic-dysfunction associated steatotic liver disease among patients with cancer. It’s a great privilege for me to work with patients with cancer to co-create their personalized lifestyle and medical management plan to help them achieve healthy goals that are meaningful to them.
In the News
Present Title & Affiliation
Dual/Joint/Adjunct Appointment
Professor, Tenured, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Experience & Service
Administrative Appointments/Responsibilities
Deputy Department Chair for Research, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - Present
Fellowship Program Director for General Internal Medicine, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - Present
Other Appointments/Responsibilities
Board Member, National Cancer Institute's PDQ Screening and Prevention Editorial Board, Rockville, MD, 2024 - Present
Member, The Texas Collaborative Center for Hepatocellular Cancer (TeCH) Clinical Network Committee, Houston, TX, 2020 - Present
Member, Cancer Center Support Grant (CCSG), Cancer Prevention Program, Houston, TX, 2020 - Present
Member, The Texas Collaborative Center for Hepatocellular Cancer (TeCH) Steering Committee, Houston, TX, 2019 - Present
Team Leader, General Internal Medicine Metabolic Quality Improvement Project, Houston, TX, 2019 - Present
Reviewer, Anal Cancer Survivorship, Houston, TX, 2015 - Present
Member, American Association for the Study of Liver Diseases Ethics Committee (AASLD), Alexandria, VA, 2013 - Present
Member, Southwest Oncology Group (SWOG), Portland, OR, 2013 - Present
Member, Research Committee, Hope Clinic, Houston, TX, 2012 - Present
Advisory Board Member, Asian Health Foundation, Parsippany, NJ, 2008 - Present
Institutional Committee Activities
Team Lead, HBV Screening and Management MD Anderson Practice Algorithm Workgroup, 2021 - Present
Leader, Patient Safety Committee Hepatitis Debrief for Hepatitis B Screening Panel, 2020 - 2020
Leader, Hepatitis B Employee Screening Committee, 2017 - Present
Content Expert, Patient Safety Committee Root Cause Analysis of Hepatitis B Core Antibody Testing, 2017
Member, Survivorship: Anal Cancer MD Anderson Cancer Survivorship Algorithm Workgroup, 2017 - Present
Judge, Scientific Posters, The University of Texas MD Anderson Cancer Center, Cancer Survivorship Research Symposium, 2016
Team Lead, Hepatitis (HBV and HCV) Screening and Management MD Anderson Practice Algorithm Workgroup, 2015 - Present
Vice-Chair, Institutional Review Board 4 (IRB 4), 2014 - 2017
Invited member, Global Academic Program Steering Committee for Yonsei University Health System, 2013
Judge, Trainee Research Day, Population/Patient-Oriented Research, 2013
Core Development Team Member, Liver Cancer Screening MD Anderson Practice Algorithm Workgroup, 2013 - Present
Member, Scientific Publications Advisory Board, 2012 - Present
Member, Survivorship Institutional Research Grant Study Section Review Committee, 2012 - 2013
Member, Survivorship Research Advisory Committee, 2011 - 2014
Member, Comprehensive Cancer Control Liver Cancer Workgroup, 2009 - Present
Member, Hepatitis B Screening Workgroup, 2009 - Present
Chair, Clinical Research & Education Unit (CREU), Department of General Internal Medicine, 2008 - Present
Member, Institutional Review Board 4, 2005 - 2017
Member, Division of Internal Medicine Research Committee, 2005 - 2007
Member, Psychosocial, Behavioral, and Health Services Research Committee, 2003 - 2006
Chair, Clinical Ethics Nominations Sub-Committee, 2002 - 2003
Member, Clinical Ethics Committee, 2001 - 2004
Member, Clinical Research Committee, 2001 - 2003
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. Strategies for patient-centered liver cancer prevention. Conference. Division of Cancer Prevention and Population Sciences Grand Rounds. Houston, TX, US.
- 2025. Lifestyle Medicine for Patients with Cancer. Conference. Hospital Medicine Department Meeting. Houston, Texas, US.
- 2025. Lifestyle Medicine for Patients with Cancer. Conference. GIM clinical and research conference. Houston, Texas, US.
- 2023. Prevention of Hepatitis B. Conference. Baylor College of Medicine. Houston, TX, US.
- 2023. Hepatitis B Screening and Management to Prevent Reactivation. Conference. The University of Texas MD Anderson Center. Houston, TX, US.
- 2023. Screening for and management of metabolic syndrome in General Internal Medicine Clinic. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2022. Hepatitis B in Cancer Patients. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2022. Patient Safety Update and Screening for and Management of Metabolic Syndrome in General Internal Medicine Clinic. Conference. Internal Medicine & Cancer Survivorship Grand Rounds. Houston, TX, US.
- 2022. Risk Factors for Liver Cancer: Hepatitis B and Fatty Liver Disease. Conference. HCA Houston Healthcare West. Houston, TX, US.
- 2021. Metabolic Syndrome Among Patients with Endometrial Cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2021. Liver Issues Among Cancer Patients: Hepatitis B and Metabolic Syndrome. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2019. Navigating the Peer Review Process. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2019. Metabolic conditions among patients with cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2017. Hepatitis B Virus Screening and Treatment in Patients with Cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2016. Potential Adverse Liver Outcomes. Conference. The University of Texas MD Anderson Cancer Center, Patient Safety Committee. Houston, TX, US.
- 2016. Protocol Development. Conference. The University of Texas MD Anderson Cancer Center, General Internal Medicine Clinical and Research Conference. Houston, TX, US.
- 2016. Perioperative Evaluation of Medical Comorbidities at a Comprehensive Cancer Center. Conference. The University of Texas MD Anderson Cancer Center, Division of Internal Medicine (DoIM) Research Retreat. Houston, TX, US.
- 2016. Management and Clinical Outcomes in Cancer Patients with Human Immunodeficiency Virus Infection Treated with Chemotherapy. Conference. The University of Texas MD Anderson Cancer Center, Division of Internal Medicine (DoIM) Research Retreat. Houston, TX, US.
- 2016. Predictors of Positive Test Results in Patients with Cancer Undergoing Hepatitis B Screening Before Chemotherapy. Conference. The University of Texas MD Anderson Cancer Center, Division of Cancer Medicine Grand Rounds. Houston, TX, US.
- 2016. Predictors of Positive Test Results in Patients with Cancer Undergoing Hepatitis B Screening Before Chemotherapy. Conference. The University of Texas MD Anderson Cancer Center, Division of Internal Medicine (DoIM) Research Retreat. Houston, TX, US.
- 2015. HBV Reactivation, Clinical Effectiveness Subcommittee Planning Meeting. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2015. HPV-associated Second Malignancies in Survivors of Allogeneic Stem Cell Transplant. Conference. The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation and Cellular Therapy. Houston, TX, US.
- 2015. Viral Reactivation in Cancer Patients. Conference. The University of Texas MD Anderson Cancer Center, 3rd Conference on Medical Issues in Cancer Patients & Survivors. Houston, TX, US.
- 2015. HIV Testing in Patients with Cancer at the Initiation of Therapy at a Large US Comprehensive Cancer Center. Conference. Division of Internal Medicine (DoIM) Research Retreat. Houston, TX, US.
- 2014. HBV Reactivation. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2014. HIV and HBV Infections in Patients with Hematologic Malignancies. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2014. HBV Reactivation, Medical Practice Committee. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2014. Management of Patients with Hepatitis B who require Immunosuppressive Therapy. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2014. Management of Patients with Hepatitis B Who Require Immunosuppressive Therapy. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2014. Institutional Databases for Outcomes Research. Conference. CITP Meeting. Houston, TX, US.
- 2013. HBV Reactivation after Chemotherapy: Screening to Prevent Reactivation. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2013. HBV Reactivation after Chemotherapy: Screening to Prevent Reactivation. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2013. Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2013. Hepatitis B Virus Screening in a Large US Cancer Center has Increased After National Recommendations. Conference. Global Academic Program (GAP) 2013 Conference. Houston, TX, US.
- 2013. Viral Reactivation after Chemotherapy, 2nd Conference on Medical Issues in Cancer Patients & Survivors. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2013. Hepatitis C Virus Screening Prior to Chemotherapy. Conference. The University of Texas MD Anderson Cancer Center, Division of Internal Medicine (DoIM). Houston, TX, US.
- 2012. Screening for Hepatitis B to Prevent Reactivation After Chemotherapy. Conference. The University of Texas MD Anderson Cancer Center, Division of Cancer Medicine Grand Rounds. Houston, TX, US.
- 2012. Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy. Conference. The University of Texas MD Anderson Cancer Center, Department of General Internal Medicine Clinical Research Education Unit (CREU) Meeting. Houston, TX, US.
- 2012. Trends in Hepatitis B Virus Screening in a Large US Cancer Center. Conference. The University of Texas MD Anderson Cancer Center, Division of Internal Medicine (DoIM). Houston, TX, US.
- 2012. Reactivation of Viral Hepatitis in Cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2012. Low Rates of Hepatitis B Virus Screening at the Onset of Chemotherapy. Conference. The University of Texas MD Anderson Cancer Center, Survivorship Meeting. Houston, TX, US.
- 2011. Reactivation of Hepatitis B Infection After Chemotherapy. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2011. Reactivation of Hepatitis B Infection Among Patients with Cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2011. Do Patients Wait Too Long? Improving Patient Wait Time in an Ambulatory Chemotherapy Unit. Conference. The University of Texas MD Anderson Cancer Center, Division of Internal Medicine Grand Rounds. Houston, TX, US.
- 2011. Do Patients Wait Too Long? Improving Patient Wait Time in an Ambulatory Chemotherapy Unit. Conference. The University of Texas MD Anderson Cancer Center, General Internal Medicine (GIM) Journal Club. Houston, TX, US.
- 2011. Reactivation of Hepatitis B Infection Among Patients with Cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2011. Reactivation of Hepatitis B Infection among Patients with Cancer. Conference. The University of Texas MD Anderson Cancer Center, Division of Internal Medicine. Houston, TX, US.
- 2011. Screening for Hepatitis B Infection to Prevent Reactivation after Chemotherapy. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2011. Estimates of Screening and Prophylaxis of Hepatitis B in Cancer Patients. Conference. American Cancer Society Institutional Research Grant. Houston, TX, US.
- 2010. Hepatitis B Screening to Prevent Reactivation. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2010. ASCO Provisional Clinical Opinion: Adherence to Hepatitis B Screening in 2 Comprehensive Cancer Centers. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2010. Hepatitis B Screening and Positivity Prior to Chemotherapy. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2010. Hepatitis B Screening and Positivity Prior to Chemotherapy. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2009. Screening and Prophylactic Treatment of Hepatitis B Virus to Prevent Reactivation. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2009. Screening for Hepatitis B and Treatment of Hepatitis B Reactivation among Cancer Patients. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2009. Natural History, Screening, Diagnosis, and Vaccination in Chronic Hepatitis B. Conference. Baylor College of Medicine. Houston, TX, US.
- 2009. Community-based Hepatitis B Research in Houston. Conference. Asian American Health Coalition HOPE Clinic. Houston, TX, US.
- 2008. Reactivation of Hepatitis B Infection among Cancer Patients. Conference. Baylor College of Medicine. Houston, TX, US.
- 2007. Hepatitis and Hepatocellular Carcinoma: A Comprehensive Cancer Center's 14 Year Experience. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2007. Frequency of Hepatitis B Virus Reactivation in Cancer Patients Undergoing Cytotoxic Chemotherapy: A Prospective Study of 626 Patients with Identification of Risk Factors. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2007. Hepatitis B and Liver Cancer: Community Based Research. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2007. Hepatitis B Reactivation among Cancer Patients: Uphill on the Race to the Finish Line. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2006. Hepatitis B in the Houston Asian American Community: Preliminary Results of a Qualitative Study". Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2006. Hepatitis B and Hepatocellular Carcinoma among Asian Pacific Islanders at a Comprehensive Cancer Center in Texas. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2006. Hepatitis B Virus and the Asian-American Community. Conference. Baylor College of Medicine. Houston, TX, US.
- 2006. Hepatitis B in the Houston Asian American Community. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2006. Hepatitis B in the Houston Asian American Community. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2004. Cardiopulmonary Resuscitation among Cancer Patients in the Emergency Center: A Three-Year Review. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2004. Hepatitis in the Houston Asian American Community. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2003. Ethics and Disparate Cancer Care, Clinical Ethics: Reflections, Evolution and Prospectives. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2003. Hepatitis B in Houston's Asian Americans: A Community-Based Approach. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2003. E Pluribus Unum: Uniting To Overcome Disparate Cancer Care. Conference. Texas Department of Health. Houston, TX, US.
- 2003. Characteristics of Cardiac Arrest in Cancer Patients as a Predictor of Survival after Cardiopulmonary Resuscitation. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2002. Disparities in Cancer Care: Predictions of Bone Marrow Transplantation in Texas. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2002. Cancer Risk Factors among Asian-Americans. Conference. KTRK-TV ABC 13. Houston, TX, US.
- 2002. A Case Study on Resource Allocation. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2002. Disparities in Cancer Care. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2001. Fatigue in the Emergency Center. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
National Presentations
- 2023. Patients with Metabolic Syndrome and Cancer: What They Know, Think, and Want. Invited. Lifestyle Medicine 2023 Conference. Denver, CO, US.
- 2022. SWOG S1614: Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors. Invited. Alliance Cancer Control Program Symptom Intervention Committee, US.
- 2022. Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Cytotoxic Therapy for Solid Tumors. Invited. OncoAlert Colloquium, US.
- 2021. SWOG S1614: Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus Infection Receiving Anti-cancer Therapy for Solid Tumor. Invited. SWOG Fall Group Meeting 2021, Symptom Control and Quality of Life Committee. Virtual, US.
- 2021. SWOG S1614: Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus Infection Receiving Anti-cancer Therapy for Solid Tumors. Invited. Hawaii MU NCORP. Virtual, US.
- 2021. “TAKE ACTION Series II: Ensuring health equity in SWOG clinical trials among Asian Americans. Why is it important to have an adequate sample size/accrual goal in clinical trials to generate knowledge for the Asian population?” https://www.swog.org/fall-2021-qm-recruitment-retention-committee-session-summary. Invited. Fall SWOG Group Meeting. Virtual, US.
- 2021. SWOG S1614: Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus Infection Receiving Anti-cancer Therapy for Solid Tumors. Invited. SWOG Fall Group Meeting, 2021, S1614 Reactivation Webinar. Virtual, US.
- 2021. Perspectives of Hispanic/Latino patients with non-alcoholic fatty liver disease. Recorded oral poster presentation. Conference. 14th American Association for Cancer Research Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, US.
- 2020. Hepatitis B ASCO Guidelines Webinar. Invited. Hep B United, US.
- 2020. Hepatitis B Virus Screening and Treatment to Prevent Hepatocellular Cancer. Invited. The Texas Collaborative Center for Hepatocellular Cancer (TeCH) Annual Symposium. Houston, TX, US.
- 2020. A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors. Invited. SWOG: S1614, US.
- 2019. A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors. Invited. SWOG: S1614, US.
- 2019. A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors. Invited. NCI. Bethesda, MD, US.
- 2019. SWOG S1614: Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus Infection Receiving Anti-cancer Therapy for Solid Tumors. Invited. SWOG Accrual Core Team (ACT) webinar, US.
- 2019. SWOG S1614: Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus Infection Receiving Anti-cancer Therapy for Solid Tumors. Invited. SWOG Cancer Research Network, US.
- 2019. Reactivation of Hepatitis B Virus among Patients with Cancer. Invited. American Association for the Study of Liver Diseases (AASLD), US.
- 2019. SWOG S1614: Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus Infection Receiving Anti-cancer Therapy for Solid Tumors. Invited. SWOG Cancer Research Network, US.
- 2019. SWOG S1614: Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus Infection Receiving Anti-cancer Therapy for Solid Tumors. Invited. SWOG NCI Community Oncology Research Program (NCORP) webinar, US.
- 2018. Overview of Oncogenic Viruses. Invited. HPV-, HBV-, HCV-, and HIV-related malignancies. Denver, CO, US.
- 2018. Reactivation of Hepatitis B Virus in Patients with Cancer. Invited. University of New Mexico, TeleECHO Clinic, US.
- 2017. S1614: Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus Infection Receiving Cytotoxic Therapy for Solid Tumors. Invited. Symptom Control and Quality of Life Committee. San Francisco, CA, US.
- 2017. Predicting Hepatitis B Virus Infection Among Patients with Cancer Undergoing Systemic Anti-cancer Therapy: A Prospective Cohort. Conference. Society for General Internal Medicine Annual Meeting (SGIM) 2017. Washington, DC, US.
- 2016. The Role of Screening to Prevent Hepatitis B Virus (HBV) Reactivation. Invited. American Association for the Study of Liver Diseases (AASLD) Hepatitis B Virus SIG Meeting. Boston, MA, US.
- 2016. Hepatocellular Carcinoma Screening in High-Risk Populations in the United States. Conference. American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2016. Boston, MA, US.
- 2016. S1614: Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus Infection Receiving Cytotoxic Therapy for Solid Tumors. Invited. Symptom Control and Quality of Life Committee. San Francisco, CA, US.
- 2015. Management of HBV in Cancer Patients, Symptom Control and Quality of Life Committee, Southwest Oncology Group (SWOG) Fall 2015 Group Meeting. Invited. Management of HBV in Cancer Patients, Symptom Control and Quality of Life Committee, Southwest Oncology Group (SWOG) Fall 2015 Group Meeting. Chicago, IL, US.
- 2015. Management of HBV in Cancer Patients. Invited. Cancer Care Delivery Research Committee. San Francisco, CA, US.
- 2014. Hepatitis Flares are Common Among Patients Receiving Chemotherapy for Cancers. Conference. American Association for the Study of Liver Diseases (AASLD). Boston, MA, US.
- 2014. HBV Reactivation After Chemotherapy in the US: Screening to Prevent Reactivation. Conference. Global Academic Program (GAP). Seoul.
- 2014. HBV Reactivation after Chemotherapy in the US: Screening to Prevent Reactivation. Invited. Global Academic Program (GAP). Seoul.
- 2013. Hepatitis B Screening to Prevent Reactivation. Invited. Conference on Reactivation of Hepatitis B. Arlington, VA, US.
- 2013. Hepatitis B Screening to Prevent Reactivation. Invited. Yale University Medical School Liver Center Research Seminar. New Haven, CT, US.
- 2013. Hepatitis B Virus Screening in a Large US Cancer Center has Increased After National Recommendations. Conference. Cancer Survivorship 2013. Houston, TX, US.
- 2013. Hepatitis B Virus Screening in a Large US Cancer Center has Increased after National Recommendations. Invited. Cancer Survivorship, US.
- 2012. Hepatitis B Screening to Prevent Reactivation at MD Anderson Cancer Center. Invited. Hepatology Grand Rounds. Dallas, TX, US.
- 2012. Low Rates of Hepatitis B Virus Screening in Cancer Patients at MD Anderson. Invited. GI Liver Conference. Ann Arbor, MI, US.
- 2011. Reactivation of Hepatitis B Infection among Patients with Cancer. Conference. American Association for the Study of Liver Diseases (AASLD), US.
- 2008. Hepatitis B 101: Reactivation of Hepatitis B Infection among Cancer Patients. Invited. Hepatitis B 101 Webcast, HEPBCME.TV, US.
- 2006. Hepatitis B and C Screening: A Collaboration between Academia and the API Community. Invited. Asian American Pacific Islander Health Summit. San Jose, CA, US.
- 2006. Hepatitis B and Hepatocellular Cancer Among Asian Americans at a Comprehensive Cancer Center in Texas. Conference. APHA 134th Annual Meeting & Exposition. Boston, MA, US.
- 2002. Disparities in Inpatient Care Among Leukemia Patients: Who Gets Bone Marrow Transplantation. Conference. 130th Annual Meeting of the American Public Health Association in Philadelphia. Philadelphia, PA, US.
International Presentations
- 2018. HBV and HCV Role in HCC Prevention and Management. Invited. Hepatocellular Carcinoma: A Global Perspective, Education Session. Chicago, US.
- 2016. Selective Screening is Effective in Identifying Patients with Hepatitis before Cancer Therapy. Conference. Oral Presentation, American Society of Clinical Oncology (ASCO) 2017 Annual Meeting. Chicago, US.
- 2016. Management and Clinical Outcomes of Cancer Patients with Human Immunodeficiency Virus After Cancer Therapy. Conference. Society of General Internal Medicine (SGIM) 2016 Annual Meeting. Toronto, CA.
- 2016. Predictors of Positive Test Results in Patients with Cancer Undergoing Hepatitis B Screening Before Chemotherapy. Conference. 2016 American Society of Clinical Oncology (ASCO) Cancer Survivorship Symposium: Advancing Care and Research - A Primary Care and Oncology Collaboration. San Francisco, US.
- 2015. Hepatitis B Virus Screening Among Rituximab-treated Patients. Conference. European Cancer Congress. Vienna, AT.
- 2015. HIV Testing in Patients with Cancer at the Initiation of Therapy at a Large US Comprehensive Cancer Center. Conference. 2015 Multinational Association of Supportive Care in Cancer MASCC/ISOO Annual Meeting. Copenhagen, DK.
- 2015. HIV Testing Among Patients with Cancer Before Initiation of Chemotherapy. Conference. 2015 Society of General Internal Medicine (SGIM) 38th Annual Meeting. Toronto, CA.
- 2014. Predictors of Positive Test Results in Patients with Cancer Undergoing Hepatitis B Screening Before Chemotherapy. Conference. American Society of Clinical Oncology (ASCO). Boston, US.
- 2013. Hepatitis C Virus Screening Prior to Chemotherapy. Conference. MASCC/ISOO Congress. Berlin, DE.
- 2012. Effect of National Recommendations on Hepatitis B Virus Screening in a Large U.S. Cancer Center. Invited. 2012 American Society of Clinical Oncology (ASCO) Quality Care Symposium. San Diego, US.
- 2012. Effect of National Recommendations on Hepatitis B Virus Screening in a Large U.S. Cancer Center. Conference. 2012 American Society of Clinical Oncology (ASCO) Quality Care Symposium. San Diego, US.
- 2011. Reactivation of Hepatitis B Infection Among Patients with Cancer. Conference. 2011 Multinational Association of Supportive Care in Cancer (MASCC) International Symposium, US.
- 2011. Reactivation of Hepatitis B Infection Among Patients with Cancer. Conference. 2011 ASCO Annual Meeting, e-Pub, US.
- 2011. Predictors of Hepatitis B Screening Among Patients with Cancer. Conference. 2011 ASCO Gastrointestinal Cancers Symposium, US.
- 2010. Hepatitis B Screening and Positivity Prior to Chemotherapy. Conference. 2010 ASCO Annual Meeting. Chicago, US.
- 2010. Hepatitis B Screening and Positivity Prior to Chemotherapy. Conference. 2010 Multinational Association of Supportive Care in Cancer (MASCC) International Symposium. Vancouver, CA.
- 2009. Hepatitis B and C Prevalence among Asian Americans Undergoing community-based Hepatitis Screening. Conference. American Association for the Study of Liver Diseases (AASLD), International Symposium on Viral Hepatitis and Liver Disease. Washington, US.
- 2008. Utilization of a Patient Medication Knowledge Tool: Implications for Medication Safety. Conference. 2008 Multinational Association of Supportive Care in Cancer (MASCC) Annual International Symposium. Houston, US.
- 2008. Medication Knowledge in a Cancer Emergency Center: Implications for Patient Safety. Invited. Multinational Association of Supportive Care in Cancer (MASCC/ISOO) 2008 International Symposium Supportive Care in Cancer. Houston, US.
- 2008. Medication Knowledge in a Cancer Emergency Center: Implications for Patient Safety. Conference. Multinational Association of Supportive Care in Cancer (MASCC/ISOO) 2008 International Symposium Supportive Care in Cancer. Houston, US.
- 2008. Hepatitis and Hepatocellular Carcinoma among Asian Pacific Islanders at a Comprehensive Cancer Center in Texas. Conference. 2008 ASCO Gastrointestinal Cancers Symposium. Orlando, US.
Formal Peers
- 2019. HBV Reactivation: How to Approach the Immunosuppressed Patient. Invited. Boston, MA, US.
- 2012. Viral Reactivation Following Biological Therapies. Invited. Boston, MA, US.
Grant & Contract Support
| Date: | 2024 - 2029 |
| Title: | Developing and Testing a Multilevel, Culturally Appropriate Lifestyle Intervention For Hispanic Patients with Metabolic-dysfunction Associated Steatotic Liver Disease |
| Funding Source: | NIH |
| Role: | Mentor |
| ID: | 1K01MD019149-01A1 |
| Date: | 2020 - Present |
| Title: | Metabolic syndrome in patients with cancer presenting to the MD Anderson General Internal Medicine Clinic: A clinical quality improvement care pathway |
| Funding Source: | Division of Internal Medicine Research and Quality Improvement Development Award |
| Role: | PI |
| Date: | 2019 - 2025 |
| Title: | Patient-centered Liver Cancer Prevention in the Houston Community |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP190513 |
| Date: | 2018 - Present |
| Title: | Human Papillomavirus (HPV)-associated Second Malignancies in Patients who Receive Allogeneic Stem Cell Transplantation |
| Funding Source: | Division of Internal Medicine Research and Quality Improvement Development |
| Role: | PI |
| Date: | 2017 - 2020 |
| Title: | SWOG S1614: A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-cancer Therapy for Solid Tumors |
| Funding Source: | Gilead |
| Role: | PI |
| Date: | 2017 - 2025 |
| Title: | Human Papillomavirus Antibody Response after GARDASIL® 9 Vaccination in Patients after Allogeneic Stem Cell Transplantation |
| Funding Source: | Merck & Co., Inc |
| Role: | PI |
| Date: | 2015 - 2019 |
| Title: | Human Papillomavirus (HPV)-Associated Second Malignancies in Patients Who Receive Allogeneic Stem Cell Transplantation: Prospective Cohort |
| Funding Source: | Duncan Family Institute Seed Funding Research Program |
| Role: | PI |
| Date: | 2013 - 2015 |
| Title: | Widespread vs. selective screening for hepatitis B infection prior to chemotherapy, CA167202-01A1 |
| Funding Source: | NIH/NCI R21 |
| Role: | PI |
| Date: | 2010 - 2016 |
| Title: | HBV reactivation among cancer patients receiving chemotherapy |
| Funding Source: | NIH/NCI K07 Career Development Award |
| Role: | PI |
| ID: | CA132955-01A2 |
| Date: | 2009 - 2011 |
| Title: | Estimates of Screening and Prophylaxis of Hepatitis B in Cancer Patients |
| Funding Source: | Bristol-Myers Squibb |
| Role: | PI |
| Date: | 2009 - 2010 |
| Title: | Estimates of Screening and Prophylaxis of Hepatitis B in Cancer Patients |
| Funding Source: | American Cancer Society (ACS) Institutional Research Grant |
| Role: | PI |
| Date: | 2007 - 2015 |
| Title: | UT MD Anderson Cancer Center CCOP Research Center |
| Funding Source: | NIH |
| Role: | Program Collaborator |
| ID: | CA04580-25 |
| Date: | 2005 - 2011 |
| Title: | Hepatitis B Knowledge and Attitudes in the Houston Asian American Community |
| Funding Source: | Gilead Sciences, Inc |
| Role: | PI |
| Title: | Human papillomavirus (HPV) surveillance and second malignancies in survivors of HPV-associated cancers |
| Funding Source: | (retracted as the Duncan Family Institute Seed Funding Research Program below was accepted) |
| Role: | PI |
| Title: | Risk factors for hepatocellular cancer in a racially and ethnically diverse community-based clinic |
| Funding Source: | NIH/NCI |
| Role: | PI |
Patient Reviews
CV information above last modified May 12, 2025